Mirum Pharmaceuticals company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

mirumpharma.com

Founded Year

2018

Stage

IPO | IPO

Total Raised

$120M

Date of IPO

7/18/2019

Market Cap

0.72B

Stock Price

22.20

About Mirum Pharmaceuticals

Mirum Pharmaceuticals is a clinical-stage therapeutics company developing an approach for treating cholestatic liver diseases, with an immediate focus on rare pediatric conditions.

Mirum Pharmaceuticals Headquarter Location

950 Tower Lane, Suite 1050

Foster City, California, 94404,

United States

650-667-4085

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Mirum Pharmaceuticals

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Mirum Pharmaceuticals in 1 CB Insights research brief, most recently on Jul 22, 2019.

Expert Collections containing Mirum Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Mirum Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Mirum Pharmaceuticals Patents

Mirum Pharmaceuticals has filed 4 patents.

The 3 most popular patent topics include:

  • Biliary tract disorders
  • Diseases of liver
  • Hepatology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/14/2020

1/25/2022

Hepatology, Diseases of liver, Inflammations, Biliary tract disorders, Pediatrics

Grant

Application Date

8/14/2020

Grant Date

1/25/2022

Title

Related Topics

Hepatology, Diseases of liver, Inflammations, Biliary tract disorders, Pediatrics

Status

Grant

Latest Mirum Pharmaceuticals News

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 11, 2022

May 10, 2022 08:05 PM Eastern Daylight Time FOSTER CITY, Calif.--( BUSINESS WIRE )--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on May 10, 2022, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 178,000 shares of common stock and 52,677 restricted stock units (“RSUs”) to 18 new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $22.55 per share, Mirum’s closing trading price on May 10, 2022, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with Mirum through the applicable vesting dates. The RSUs will vest over three years, with 33% of the underlying shares vesting on each anniversary of the applicable vesting commencement date, subject to the new employees’ continued service relationship with Mirum through the applicable vesting dates. The awards are subject to the terms and conditions of Mirum’s 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. Mirum’s approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older. Please view the warnings and precautions available in the Prescribing information or, for more information, visit LIVMARLI.com. Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. Maralixibat (LIVMARLI), an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 study for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b study for patients with biliary atresia. In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC. Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for maralixibat for the treatment of cholestatic liver disease in patients with Alagille syndrome. Mirum’s second investigational treatment, volixibat, an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the VISTAS Phase 2b clinical trial for adults with primary sclerosing cholangitis, the OHANA Phase 2b clinical trial for pregnant women with intrahepatic cholestasis of pregnancy, and the VANTAGE Phase 2b clinical trial for adults with primary biliary cholangitis. Contacts

Mirum Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Mirum Pharmaceuticals Rank

  • When was Mirum Pharmaceuticals founded?

    Mirum Pharmaceuticals was founded in 2018.

  • Where is Mirum Pharmaceuticals's headquarters?

    Mirum Pharmaceuticals's headquarters is located at 950 Tower Lane, Suite 1050, Foster City.

  • What is Mirum Pharmaceuticals's latest funding round?

    Mirum Pharmaceuticals's latest funding round is IPO.

  • How much did Mirum Pharmaceuticals raise?

    Mirum Pharmaceuticals raised a total of $120M.

  • Who are the investors of Mirum Pharmaceuticals?

    Investors of Mirum Pharmaceuticals include New Enterprise Associates, Frazier Healthcare Partners, RiverVest Venture Partners, Novo Holdings, Pappas Ventures and 5 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.